PUBLIKACE A PROPAGACE Sample Clauses

PUBLIKACE A PROPAGACE. Publication 5.1
Sample 1Sample 2Sample 3See All (36)
AutoNDA by SimpleDocs
PUBLIKACE A PROPAGACE. It is understood that the Study is part of a multicenter trial, and Healthcare Provider may publish, only upon Sponsor’s approval, the results of its part of the Study in collaboration with the other investigators, but in complete compliance with this section and with the Confidential Information section. After the multicenter publication or 12 months after completion of the Study, whichever occurs first, Healthcare Provider may itself publish the results of its data from the Study. Healthcare Provider and Principal Investigator shall provide Sponsor and Cmed with an advance copy of any proposed publication or oral presentation at least 60 days prior to the planned date of submission or presentation and Sponsor [and Cmed] shall have 60 days to review the proposed publication for A. Rozumí se, že studie je součástí multicentrického hodnocení a poskytovatel zdravotních služeb může se souhlasem zadavatele zveřejnit výsledky své části studie ve spolupráci s ostatními zkoušejícími, avšak zcela v souladu s tímto bodem a s bodem Důvěrné informace. Poskytovatel zdravotních služeb může sám zveřejnit výsledky svých údajů ze studie po multicentrické publikaci nebo 12 měsíců od dokončení studie. Poskytovatel zdravotních služeb a hlavní zkoušející poskytnou zadavateli a společnosti Cmed předem kopii navrhované publikace nebo ústní prezentace, a to nejméně 60 dnů před plánovaným datem předání nebo prezentace, a zadavatel [a společnost Cmed] budou mít 60 dnů na posouzení navrhované publikace ke schválení a pro níže
Sample 1
PUBLIKACE A PROPAGACE. It is understood that the Study is part of a multicenter trial, and Institution may publish, only upon Sponsor’s approval, the results of its part of the Study in collaboration with the other investigators, but in complete compliance with this section and with the Confidential Information section. After the multicenter publication or 12 months after completion of A. Rozumí se, že studie je součástí multicentrického hodnocení a zdravotnické zařízení může se souhlasem zadavatele zveřejnit výsledky své části studie ve spolupráci s ostatními zkoušejícími, avšak zcela v souladu s tímto bodem a s bodem Důvěrné informace. Zdravotnické zařízení může the Study, whichever occurs first, Institution may itself publish the results of its data from the Study. Institution and Principal Investigator shall provide Sponsor and Cmed with an advance copy of any proposed publication or oral presentation at least 60 days prior to the planned date of submission or presentation and Sponsor [and Cmed] shall have 60 days to review the proposed publication for approval and the purposes described below. Sponsor and Cmed may request in writing, and Institution shall, inasmuch as the scientific nature of the publication is not impaired as a result, agree to, (a) the deletion of any Confidential Information, (b) any reasonable changes requested by Sponsor or Cmed, or (c) a delay of such proposed submission for an additional period, not to exceed 180 days, in order to protect its proprietary information and/or Intellectual Property Rights and Know How resulting from the Study. samo zveřejnit výsledky svých údajů ze studie po multicentrické publikaci nebo 12 měsíců od dokončení studie. Zdravotnické zařízení a hlavní zkoušející poskytnou zadavateli a společnosti Cmed předem kopii navrhované publikace nebo ústní prezentace, a to nejméně 60 dnů před plánovaným datem předání nebo prezentace, a zadavatel [a společnost Cmed] budou mít 60 dnů na posouzení navrhované publikace ke schválení a pro níže uvedené důvody. Zadavatel a společnost Cmed mohou písemně požadovat a zdravotnické zařízení bude souhlasit, pokud tím nebude narušena vědecká povaha publikace, s (a) odstraněním všech důvěrných informací, (b) přiměřenými změnami požadovanými zadavatelem nebo společností Cmed, nebo (c) odkladem tohoto navrhovaného předání o další období, které nebude xxxxx xxx 000 xxx, xx účelem ochrany svých chráněných informací nebo práv duševního vlastnictví a know-how, které ze studie vyplývají.
Sample 1
PUBLIKACE A PROPAGACE. The Service Provider shall not publish any articles or papers or make any presentations, nor assist any other person in publishing any articles or papers or making any presentations, relating or referring to the Study, the Confidential Information and/or the Intellectual Property, without the prior written consent of PSI and the Sponsor, in their sole discretion.
Sample 1

Related to PUBLIKACE A PROPAGACE

  • Publikace The Institution and the Investigator agree that the Sponsor shall have the sole and exclusive right to the first publication of the results of the Study. Such Sponsor publication is intended to be a multi-center publication of the Study results, collected from all investigators and institutions participating in the Study (the “Multi- Center Publication”). If the Investigator is interested in contributing to or participating in the Multi-Center Publication, he or she must contact the Sponsor. Selection of authors/participants will be governed by the Sponsor, considering individuals’ contribution to the Study.

  • Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!